Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 2:02 PM
Ignite Modification Date:
2025-12-25 @ 12:47 PM
NCT ID:
NCT00622895
Group ID:
EG000
Title:
Treatment: Allogeneic HCT After Reduced Intensity Conditioning
Description:
Patients receive fludarabine phosphate IV on days -4, -3 and -2, cyclophosphamide IV over 1-2 hours on days -6, -5, 3, and 4, and undergo low-dose TBI on day -1. Patients receive bone marrow transplantation on day 0. Patients then receive cyclophosphamide IV on days +3 and +4, and beginning day +5 they start tacrolimus orally (PO) and mycophenolic acid.
fludarabine phosphate: Given IV
Mycophenolic Acid: Given PO
tacrolimus: Given PO
total-body irradiation: Undergo TBI
bone marrow transplantation: Undergo transplantation
reduced intensity allogeneic hematopoietic stem cell transplantation: Undergo transplantation
quality-of-life assessment: Ancillary studies
laboratory biomarker analysis: Correlative studies
flow cytometry: Correlative studies
biopsy: Punch biopsy of skin involved with scleroderma
cyclophosphamide: Given IV
Deaths Number Affected:
2
Deaths Number At Risk:
None
Serious Number Affected:
2
Serious Number At Risk:
3
Other Number Affected:
1
Other Number At Risk:
3
Study:
NCT00622895
Results Section:
NCT00622895
Adverse Events Module:
NCT00622895